SUPPORTING FIGURES
. Chemical structures and water solubility of (i) SH7133 (primary aminefunctionalized SHAL), (ii) SH7139 (DOTA-functionalized SHAL), and (iii) SH7129 (biotinfunctionalized SHAL). SH7139 and SH7129 were prepared from SH7133. The synthesis, purification, and characterization of all SHALs were reported in references 21, 22, 29 and 58. Figure S4 . Ultraviolet-visible spectra of amine-functionalized SHAL (SH7133, 1 mg/mL in DMSO, 516 µM) and purified SHAL-functionalized PEG-PLA (1 mg/mL in DMSO). The extinction coefficient of SH7133 at 454 nm was 21,500 M -1 cm -1 . It was calculated that 52.7 mol% of the PEG-PLA was functionalized with SH7133 (conjugation efficiency ≈ 59%, since 90% of the PEG-PLA was functionalized with the NHS ester). The inset shows a digital image of the SHAL-functionalized PEG-PLA (1 mg/mL in DMSO). . Drug release kinetics at neutral (pH 7.0) and different mild acidic (either 6.5 or pH 5.5) conditions. Averaged time-dependent ultraviolet-visible spectra of (i) non-targeted Dox NPs and (ii) SHAL-functionalized Dox NPs after incubation in a large excess of 1X PBS at pH 5.5, 6.5 or 7.0 at 37 °C. The concentrations of both NPs were 2 mg/mL. The drug-encapsulation efficiencies of the non-targeted Dox NPs and SHAL-functionalized Dox NPs were 56.7 ± 1.0% (i.e., 1 mg NPs contains 28.4 µg encapsulated Dox) and 57.8 ± 1.1% (i.e., 1 mg NPs contains 28.9 µg encapsulated Dox), respectively. (n = 3). Table S2 . Table summarizing the absolute growth delay, normalized growth delay and enhancement factor (E.F.) of Daudi-xenograft tumor bearing mice after receiving different chemo-immunotherapy and concurrent CIRT treatment. [ a Absolute growth delay (A.G.D.) caused by Dox and/or SHAL (co)treatment with/without concurrent XRT is defined as the time in day(s) tumors required to reach 1,000 mm 3 post-inoculation minus the time in days untreated tumors required to grow to 1,000 mm 3 . b Normalized growth delay (N.G.D.) is defined as time in days for tumors to reach 1,000 mm 3 post-inoculation in mice treated by free/encapsulated Dox with/without free/conjugated SHAL plus radiation minus the time in days for tumors to reach 1,000 mm 3 post-inoculation in mice only received chemotherapy. c Enhancement factors (E.F.): obtained by dividing normalized tumor growth delay in mice treated with different chemotherapy plus radiation by the absolute growth delay in mice treat with radiation only. N/A denotes no enhancement (i.e., E.F. < 1 Free SHAL + free Dox + XRT 72.2 ± 0.9 33.5 ± 0.9 12.5 ± 0.9 N/A SHAL NPs + non-targeted Dox NPs + XRT 71.4 ± 1.9 32.7 ± 1.9 11.7 ± 1.9 N/A Table S3 . Table summarize the absolute growth delay, normalized growth delay and enhancement factor (E.F.) of Raji-xenograft tumor bearing mice after receiving different chemo-immunotherapy and concurrent CIRT treatment. [ a Absolute growth delay (A.G.D.) caused by Dox and/or SHAL (co)treatment with/without concurrent XRT is defined as the time in day(s) tumors required to reach 1,000 mm 3 post-inoculation minus the time in days untreated tumors required to grow to 1,000 mm 3 . b Normalized growth delay (N.G.D.) is defined as time in days for tumors to reach 1,000 mm 3 post-inoculation in mice treated by free/encapsulated Dox with/without free/conjugated SHAL plus radiation minus the time in days for tumors to reach 1,000 mm 3 post-inoculation in mice only received chemotherapy. c Enhancement factors (E.F.): obtained by dividing normalized tumor growth delay in mice treated with different chemotherapy plus radiation by the absolute growth delay in mice treat with radiation only. N/A denotes no enhancement (i.e., E.F. < 1).]
